Actively Recruiting
An Outcome Analysis of Primary Membranous Nephropathy
Led by Mario Negri Institute for Pharmacological Research · Updated on 2026-03-23
500
Participants Needed
2
Research Sites
1539 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an observational study intended to track the course of the primary membranous nephropathy disease in real-world clinical practice. The study will primarily assess the long-term outcomes of patients with primary membranous nephropathy in the context of advances in treatment options.
CONDITIONS
Official Title
An Outcome Analysis of Primary Membranous Nephropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (18 years old or older) on the day of signing informed consent
- Diagnosis of primary membranous nephropathy
- Nephrotic syndrome with proteinuria greater than 3.5 grams per 24 hours
- Written informed consent to use recorded data for research
You will not qualify if you...
- Legal incapacity or limited legal capacity
- Any contraindication to treatment with rituximab or other monoclonal antibody
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
ASST HPG23 - Unità di Nefrologia
Bergamo, BG, Italy, 24127
Active, Not Recruiting
2
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"
Ranica, BG, Italy, 24020
Actively Recruiting
Research Team
M
Matias Trillini, MD
CONTACT
P
Piero L Ruggenenti, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here